Pharmacotherapy and behavioral intervention for peripheral arterial disease.
Lower-extremity peripheral arterial disease is a chronic disease process resulting from atherosclerotic obstruction of major vessels supplying the legs. A significant manifestation of systemic atherosclerosis, it is estimated to affect more than 10 million adults in the United States alone. The reported incidence is a conservative estimate, because many patients who suffer from symptoms of peripheral arterial disease attribute them to "normal aging" and may not report them to their physician. Additionally, physicians may miss the diagnosis if a comprehensive history and vascular examination are not a routine part of their assessment. The hallmark symptom of peripheral arterial disease is intermittent claudication, defined as reproducible muscular leg pain that is precipitated by exercise and relieved by rest. Intermittent claudication not only limits functional capacity and adversely affects quality of life but is also an ominous predictor of increased risk for myocardial infarction, stroke, and cardiovascular death. Due to the chronicity of atherosclerosis, medical intervention is most successful when a comprehensive team approach is utilized, involving the patient, family, and vascular health professionals. Treatment for peripheral arterial disease is aimed at first, minimizing symptoms and disease progression via smoking cessation, supervised exercise therapy, pharmacotherapy, and/or revascularization, and second, minimizing the risk of cardiovascular mortality via risk factor identification and reduction, and the use of antiplatelet therapy.
Doyle
Jeanne
J
Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
Creager
Mark A
MA
D001157:Arterial Occlusive Diseases / Q000188:drug therapy / Q000628:therapy*; D001161:Arteriosclerosis / Q000628:therapy; D018450:Disease Progression; D005081:Exercise Therapy; D006801:Humans; D007383:Intermittent Claudication / Q000628:therapy; D008019:Life Style; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012307:Risk Factors
D010975:Platelet Aggregation Inhibitors